Back to search

Article

Tandem CD19/CD22 CAR-T cells conquer high-risk cytogenetics and acquire complete remission in r/r B-ALL patients

2022-09-26

Abstract excerpt

<h4>Background: </h4> CD19 chimeric antigen receptor T cells (CAR-T cells) have demonstrated impressive response rates in relapse and refractory B acute lymphoblastic leukemia (r/r B-ALL). However, a high rate of patients suffered a CD19-negative (CD19 − ) relapse, and confers dismal outcomes. Dual targets approaches are proved to optimize the response rate and prevent antigen negative relapse. While for r/r B-ALL...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
77abb27c-43ac-5d03-9ff7-9c0731cb9ea7
DOI
10.21203/rs.3.rs-2085779/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Tandem CD19/CD22 CAR-T cells conquer high-risk cytogenetics and acquire complete remission in r/r B-ALL patientsDOI 10.21203/rs.3.rs-2085779/v1
Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia.Semantic proximity
Treatment Outcome of Pediatric B-ALL with Bone Marrow and Extramedullary Relapse by Anti-CD19 CAR-TSemantic proximity
Unraveling Cellular and Molecular Mechanisms of Relapse in CD19/CD22 Dual-Targeting CAR T Therapy for B-ALLSemantic proximity
A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALLSemantic proximity
MRD-Negative Remission Induced in EP300-ZNF384 Positive B-ALL Patients by Tandem CD19/CD22 CAR T-Cell Therapy Bridging to Allogeneic Stem Cell TransplantationSemantic proximity
Future perspectives on novel CAR-T therapeutics beyond CD19 and BCMA in onco-hematologySemantic proximity
Prophylactic donor-derived CD19 CAR-T cell infusion for preventing relapse in high-risk B-ALL after allogeneic hematopoietic stem cell transplantationSemantic proximity
CAR-T cells with the CD38-CD73-Tim-3-HLA-DR+ phenotype predict the efficacy of tisagenlecleucel as a treatment for B cell precursor ALL.Semantic proximity
Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALLSemantic proximity
Anti-CD19 CAR T as a feasible and safe therapy for refractory/relapsed mixed phenotype acute leukemia (MPAL) patientsSemantic proximity
CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CARSemantic proximity
Favorable response of a patient with primary B/myeloid mixed phenotype acute Leukemia to CD19-CAR-T: Case report and literature review.Semantic proximity
Select a neighboring publication to make it the new centre.